
PMN Stock Forecast & Price Target
PMN Analyst Ratings
Bulls say
ProMIS Neurosciences Inc. is positioned favorably within the biotechnology sector due to its advanced Alzheimer’s therapy candidate, PMN310, which has demonstrated a strong safety profile with a low incidence of amyloid-related imaging abnormalities (ARIA), potentially surpassing existing anti-amyloid treatments. The company’s Phase Ib PRECISE-AD study is over 85% enrolled, indicating robust ongoing clinical progress, with 6-month data expected in the second quarter of 2026, signaling a timely path to significant clinical milestones. Moreover, the burgeoning Alzheimer’s market presents a substantial commercial opportunity, enhancing the potential for ProMIS to capitalize on its innovative therapeutic approaches targeting neurodegenerative diseases.
Bears say
ProMIS Neurosciences Inc reported a net loss of $11.6 million for the third quarter of 2025, translating to a loss of $0.24 per share, indicating significant ongoing financial challenges that may hinder growth potential. The company faces critical risks, including the inability to demonstrate safety and efficacy of its lead candidate PMN310 compared to existing anti-amyloid therapies, which could jeopardize regulatory approvals in a competitive market. Additionally, the need for future financing raises concerns about possible dilution for existing shareholders, compounding the company's negative outlook amidst the increasing prevalence of Alzheimer's disease and associated market potential.
This aggregate rating is based on analysts' research of ProMIS Neurosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
PMN Analyst Forecast & Price Prediction
Start investing in PMN
Order type
Buy in
Order amount
Est. shares
0 shares